Mode of Administration: Intravenous
Sponsors
Reliance Life sciences Pvt Ltd, Intas Pharmaceuticals Ltd, Intas Pharmaceuticals Limited, Ayana Pharma Ltd, Celerity Pharmaceuticals LLC
Conditions
Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 1: C569- Malignant neoplasm of unspecifiedovaryHealth Condition 1: Z854- Personal history of malignant neoplasm of genital organsHealth Condition 1: null- Patients with Non-Hodgkinâ??s Lymphoma
Phase 1
Phase 3
To study the effects of two drugs, R-TPR-017 and Mabthera® (Ristova®) in cancer patients (Non-Hodgkinâ??s Lymphoma)
Active, not recruitingCTRI/2011/12/002232
Target: 105Updated: 2021-11-24
A study to evaluate the efficacy and safety of Test product (Docetaxel of Intas Pharmaceuticals) compared to Reference product (Docetaxel of Sanofi-Aventis) in breast cancer patients.
RecruitingCTRI/2018/06/014390
Target: 657Updated: 2026-04-27
Phase 4
A study of Docetaxel Lipid Suspension for Injection in patients with cancer of a gland of the male reproductive system
Active, not recruitingCTRI/2018/02/012212
Target: 86Updated: 2021-11-24
A study of INTP26 (trastuzumab) in patients with breast cancer or gastric cancer.
Active, not recruitingCTRI/2019/09/021092
Target: 200Updated: 2021-11-24
Unknown Phase
A comparative study of Doxorubicin Hydrochloride (Pegylated Liposomal) in patients with a cancer of female organs that produce eggs
Active, not recruitingCTRI/2018/01/011498
Target: 66Updated: 2021-11-24
A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects with Ovarian Cancer.
Active, not recruitingCTRI/2018/07/014835
Target: 42Updated: 2021-11-24
A Study of Doxorubicin Hydrochloride Liposome Injection in Patients with Ovarian Cancer.
Active, not recruitingCTRI/2018/08/015266
Target: 76Updated: 2021-11-24
A Study of Doxorubicin Hydrochloride Injection in Patients with Breast Cancer
Active, not recruitingCTRI/2018/08/015325
Target: 76Updated: 2021-11-24